Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Shareholder Meeting (November 2014)
17 slides from Genetic Technologies's shareholder meeting presentation, Nov 25, 2014
Slide 1: ASX Announcement: 2014 Annual General Meeting
ASX ANNOUNCEMENT 25 November 2014 2014 Annual General Meeting Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to release the attached slide show presentation which will be delivered by its Chief Executive Officer, Ms. Alison Mew, at the Company’s 2014 Annual General Meeting to be he
Slide 2: Genetic Technologies Limited Annual General Meeting
Genetic Technologies Limited Annual General Meeting Tuesday, 25 November 2014
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements/performance
Slide 4: Summary - major achievements since last AGM
Summary - major achievements since last AGM . Strategic Review of GTG business and growth opportunities . Phenogen strategic shift and focus on breast and imaging centers to accelerate growth . Development and launch of BREVAGenplus in October 2014 . Clinical Utility studies for BREVAGenplus designe
Slide 5: Strategic Review
Strategic Review . Board and Management review of company assets: –Heritage businesses – little opportunity for growth, sample numbers trending downwards –RareCellect – technology being superseded, patent portfolio costly, time limit on divestment activities –Divestment of other non-core assets –Lic
Slide 6: What is BREVAGenplus?
What is BREVAGenplus? . BREVAGenplus is a simple swab-based test that can help determine a woman’s risk of developing breast cancer . Genetic risk is combined with clinical risk from the Breast Cancer Risk Assessment Tool (“BCRAT”) to provide an integrated risk score . Molecular panel of over 70 SNP
Slide 7: Launching BREVAGenplus
Launching BREVAGenplus . Launched 6 October 2014 . Featured on 17 news affiliates - television segments across the country . Radio news features and talkback health programs . Multimedia and websites eg. Yahoo! Finance, Reuters . Print media – trade publications, national and local news media . Soci
Slide 8: Media Coverage
Media Coverage . The BREVAGenplus logo with the tagline was seen on the Reuters billboard in Times Square from October 6 – 8. . To-date, the news release has resulted in: . 6,699 online views . 1,540 online video views . 32 total file downloads (images, video, etc.)
Slide 9: Field Sales Customer Mix
Field Sales Customer Mix: 65% ObGyns/Surgeons -- 35% Breast Centers Independent MDs High-Potential MD groups Breast/Imaging Centers Traditional Strategic 65% 35% Customer Type Regional Business Manager Regional Business Manager + Director Strategic Accounts ‘Key Account’ ‘Strategic Account’
Slide 10: Strategic Accounts: To commence Nov 2014–January 2015
Strategic Accounts: To commence Nov 2014– January 2015 Breast/Imaging Centers West Region East Region • Good Samaritan (CA) • Pink Lotus (CA) • St Johns (CA) • Aurora Breast Center (WI) • Creighton (NE) • Evergreen (WA) • St Luke’s (KS) • Exempla (CO) • Atlantic Healthcare System (NJ) • Breast Care
Slide 11: Spreading the Story: Conference Exhibits 2014
Spreading the Story: Conference Exhibits 2014 . Miami Breast Cancer Conference (Feb 2014) . National Consortium of Breast Centers (March 2014) . Take the Lead in Breast Cancer Care (April & Nov 2014) . American Society of Breast Surgeons (May 2014) . Sister’s Network: Annual National African-America
Slide 12: Spreading the Story: Conference Exhibits 2014 (contd)
Spreading the Story: Conference Exhibits 2014(contd) . New Jersey OBGYN Society (June 2014) . Colorado ACOG Section Meeting (June 2014) . Utah Association of Genetic Counselors (June 2014) . Omnia Education Women’s Health Visit Series (Multiple metropolitan areas, 2014) . Advanced Practice in Primar
Slide 13: Geographical Clustering of Samples: 2014
Geographical Clustering of Samples: 2014
Slide 14: BREVAGen sample growth: Performance to date
BREVAGen sample growth: Performance to date
Slide 15: Reimbursement Improvement
Additional studies published to include: • Hispanic American • African American • Expanded SNP panel Clinical Utility Studies to drive MRI and/or chemoprevention Improved BREVAGen Reimbursement Contract directly with large Self-Insured Employer Groups Contract directly with Insurers Contracting with
Slide 16: Key Market Drivers
Key Market Drivers . Validation and Clinical Utility - Additional clinical validation publications expected in early to mid 2015: - Expanded SNP panel, Caucasians, African American and Hispanic - Clinical utility studies, conducted in association with key breast centers, will increase reimbursement
Slide 17: Priorities for FY2015
Priorities for FY2015 . Strengthen the Phenogen sales team, focus on improving scalability and market awareness of BREVAGenplus . Find, establish and grow key accounts (breast centers, radiology centers) in the U.S. market . Monitor the release of 2nd generation BREVAGenplus to improve performance,
Genetic Technologies — Shareholder Meeting (November 2014) on 6ix